# A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Source: https://onco.cc/trials/nct05170958/  
OnCo record `nct05170958` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LBL-024 for Injection in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05170958 by Nanjing Leads Biolabs Co.,Ltd, with 396 participants planned, started 2022-01-06 and due to reach its primary completion in 2026-12. Interventions recorded: LBL-024 for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05170958
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 396

## Sources

- ClinicalTrials.gov NCT05170958: https://clinicaltrials.gov/study/NCT05170958

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct05170958.json